{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:29Z","timestamp":1786988069720,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"am","delay-in-days":670,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115776","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T11:26:49Z","timestamp":1693394809000},"page":"115776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Tetrahydro-\u03b2-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity"],"prefix":"10.1016","volume":"260","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-7655","authenticated-orcid":false,"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyun","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael R.","family":"Steimbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubry K.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofa","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiadong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115776_bib1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2217\/epi-2022-0437","article-title":"The landscape of histone modifications in epigenomics since 2020","volume":"14","author":"Shirvaliloo","year":"2022","journal-title":"Epigenomics"},{"key":"10.1016\/j.ejmech.2023.115776_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-15-8104-5_1","article-title":"Overview of histone modification","volume":"1283","author":"Zhang","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2023.115776_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112171","article-title":"Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: a review","volume":"192","author":"Sarkar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215472","article-title":"Histone deacetylase functions in gastric cancer: therapeutic target?","volume":"14","author":"Badie","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115776_bib5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.drudis.2022.02.009","article-title":"Histone deacetylase inhibitor-based oncolytic virotherapy: a promising strategy for cancer treatment","volume":"27","author":"Shirbhate","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115776_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2023.115776_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.115776_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2023.115776_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2023.115776_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ejmech.2023.115776_bib11","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-15-0530","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115776_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2016.07.001","article-title":"Romidepsin for the treatment of relapsed\/refractory cutaneous T-cell lymphoma (mycosis fungoides\/Sezary syndrome): use in a community setting","volume":"106","author":"Reddy","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2023.115776_bib13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115776_bib14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115776_bib15","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/jm4001659","article-title":"Development and therapeutic implications of selective histone deacetylase 6 inhibitors","volume":"56","author":"Kalin","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5582\/ddt.2013.v7.6.233","article-title":"HDAC6: physiological function and its selective inhibitors for cancer treatment","volume":"7","author":"Yang","year":"2013","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.ejmech.2023.115776_bib17","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1074\/jbc.M808999200","article-title":"HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling","volume":"284","author":"Kekatpure","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molcel.2007.05.033","article-title":"HDAC6 modulates cell motility by altering the acetylation level of cortactin","volume":"27","author":"Zhang","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2023.115776_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/emmm.201201923","article-title":"Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease","volume":"5","author":"Govindarajan","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115776_bib20","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.ejmech.2017.10.040","article-title":"Recent advances in the discovery of potent and selective HDAC6 inhibitors","volume":"143","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib21","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106622","article-title":"Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: structure, function and design","volume":"138","author":"Peng","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129148","article-title":"Discovery of indole-piperazine derivatives as selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting activities and neuroprotective activities","volume":"81","author":"Liang","year":"2023","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115776_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejmech.2019.02.032","article-title":"Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors","volume":"168","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib25","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1248\/cpb.c19-00425","article-title":"Design, synthesis and biological evaluation of novel benzoylimidazole derivatives as raf and histone deacetylases dual inhibitors","volume":"67","author":"Chen","year":"2019","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejmech.2023.115776_bib26","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1248\/cpb.c20-00056","article-title":"Discovery of 1,3-disubstituted 2,5-diketopiperazine derivatives as potent class I HDACs inhibitors","volume":"68","author":"Gong","year":"2020","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejmech.2023.115776_bib27","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.1021\/ja102758v","article-title":"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A","volume":"132","author":"Butler","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115776_bib28","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115776_bib29","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.18632\/oncotarget.13738","article-title":"Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2023.115776_bib30","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1021\/acsmedchemlett.9b00560","article-title":"Structural and in vivo characterization of tubastatin A, a widely used histone deacetylase 6 inhibitor","volume":"11","author":"Shen","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115776_bib31","doi-asserted-by":"crossref","first-page":"15704","DOI":"10.1073\/pnas.1313893110","article-title":"Development of a histone deacetylase 6 inhibitor and its biological effects","volume":"110","author":"Lee","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115776_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113815","article-title":"A review of synthetic bioactive tetrahydro-beta-carbolines: a medicinal chemistry perspective","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib33","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/jm0300577","article-title":"The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues","volume":"46","author":"Daugan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib34","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1021\/jm030056e","article-title":"The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues","volume":"46","author":"Daugan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib35","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1193225","article-title":"Spiroindolones, a potent compound class for the treatment of malaria","volume":"329","author":"Rottmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115776_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuropharm.2015.07.011","article-title":"Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats","volume":"99","author":"Mitsui","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2023.115776_bib37","doi-asserted-by":"crossref","first-page":"8128","DOI":"10.1021\/acs.jmedchem.5b00984","volume":"58","author":"De Savi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111950","article-title":"Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: rational design, synthesis and antiproliferative activity","volume":"187","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115776_bib39","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1021\/ja00543a012","article-title":"General method for the assignment of stereochemistry of 1,3-disubstituted 1,2,3,4-tetrahydro-P-carbolines by carbon-13 spectroscopy","volume":"102","author":"Ungemach","year":"1980","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2023.115776_bib40","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","article-title":"A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases","volume":"95","author":"Richon","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.115776_bib41","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1021\/acs.jmedchem.8b01936","article-title":"Selective inhibition of histone deacetylase 10: hydrogen bonding to the gatekeeper residue is implicated","volume":"62","author":"Geraldy","year":"2019","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:27Z","timestamp":1759330827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423007432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":41,"alternative-id":["S0223523423007432"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115776","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetrahydro-\u03b2-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115776"}}